Filing Details
- Accession Number:
- 0001179110-19-003315
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2019-03-05 17:31:58
- Reporting Period:
- 2019-03-01
- Accepted Time:
- 2019-03-05 17:31:58
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1597264 | Blueprint Medicines Corp | BPMC | Pharmaceutical Preparations (2834) | 000000000 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1663022 | Kate Haviland | C/O Blueprint Medicines Corporation 45 Sidney Street Cambridge MA 02139 | Chief Operating Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2019-03-01 | 14,144 | $16.28 | 20,018 | No | 4 | M | Direct | |
| Common Stock | Acquisiton | 2019-03-01 | 7,500 | $36.05 | 27,518 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2019-03-01 | 21,644 | $85.05 | 5,874 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (Right to Buy) | Acquisiton | 2019-03-01 | 32,500 | $0.00 | 32,500 | $86.60 |
| Common Stock | Restricted Stock Units | Acquisiton | 2019-03-01 | 8,750 | $0.00 | 8,750 | $0.00 |
| Common Stock | Stock Option (Right to Buy) | Disposition | 2019-03-01 | 14,144 | $0.00 | 14,144 | $16.28 |
| Common Stock | Stock Option (Right to Buy) | Disposition | 2019-03-01 | 7,500 | $0.00 | 7,500 | $36.05 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 32,500 | 2029-03-01 | No | 4 | A | Direct | |
| 8,750 | No | 4 | A | Direct | ||
| 33,495 | 2026-02-01 | No | 4 | M | Direct | |
| 24,000 | 2027-02-16 | No | 4 | M | Direct |
Footnotes
- The exercises reported on this Form 4 was effected pursuant to a trading plan adopted on December 21, 2017 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended (the "Exchange Act").
- The sales reported on this Form 4 were effected pursuant to a trading plan adopted on December 21, 2017 pursuant to Rule 10b5-1 under the Exchange Act.
- The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $85.00 to $85.58 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- This option vests with respect to 1/48th of the shares underlying the option on April 1, 2019 and as to an additional 1/48th of the shares underlying the option each month thereafter.
- Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
- The restricted stock units vest in four equal annual installments on March 1, 2020, 2021, 2022 and 2023.
- This option was granted on February 1, 2016. This option vested with respect to 25% of the shares underlying the option on January 5, 2017 and as to an additional 1/48th of the shares underlying the option each month thereafter.
- This option was granted on February 16, 2017. This option vested with respect to 1/48th of the shares underlying the option on March 16, 2017 and as to an additional 1/48th of the shares underlying the option each month thereafter.
Billionaire Hedge Funds
